logo-loader

Aegle Therapeutics Corp

Receive alerts
Market:
PRIVATE
Market Cap:
£0.00
Price
0.00 0
Change
0%
52 weeks high
0
52 weeks low
0

In brief

Aegle Therapeutics CEO Shelley Hartman joined Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. 

The Phase 1/2a ready company isolating extracellular vesicles from allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions, including burns and epidermolysis bullosa, a rare pediatric connective tissue disorder, and to prevent scarring.